[Treatment of chronic recurring parotitis with the protease inhibitor aprotinin (trasylol)].
Excessive release of glandular kallikrein into the interstitial space around the salivary gland ducts plays a significant role in chronic recurrent parotitis. In the present study 26 patients suffering from acute exacerbated chronic recurrent parotitis were subjected to treatment with the kallikrein inhibitor aprotinin (Trasylol, Bayer AG). During the first hour of treatment 1 mio KIU Aprotinin were infused intravenously, followed by 250 000 KIU/h for another 35 h. Within 12 h after initiation of therapy in all patients we observed remission of pain. Salivary gland function which had been seriously impaired prior to therapy was found to be largely normalized within 48 h in most patients treated in this way. The success of this therapy schedule underlines the suggestion that glandular kallikrein is a trigger enzyme in the pathogenesis of chronic recurrent parotitis.
H
H
Maier
D
D
Adler
D007611:Aprotinin / Q000627:therapeutic use*; D002908:Chronic Disease; D006801:Humans; D007263:Infusions, Parenteral; D007610:Kallikreins / Q000378:metabolism; D010309:Parotitis / Q000188:drug therapy*; D012463:Saliva / Q000187:drug effects; D012472:Salivation / Q000187:drug effects; D012636:Secretory Rate / Q000187:drug effects
D007611:Aprotinin; D007610:Kallikreins
Die Behandlung der chronisch-rezidivierenden Parotitis mit dem Proteasen-Inhibitor Aprotinin (Trasylol).